阿奇霉素联合特布他林雾化吸入治疗小儿支原体肺炎的效果探讨

The Effect of Azithromycin Combined with Terbutaline Nebulized Inhalation in the Treatment of Mycoplasma Pneumonia in Children

目的阿奇霉素联合特布他林雾化吸入治疗小儿支原体肺炎(MMP)的效果观察。方法纳入该院2019年4月—2020年4月期间收治的74例MMP患儿展开研究分析,按入院时间的先后顺序,分为对照组(阿奇霉素序贯治疗)与研究组(阿奇霉素序贯+特布他林雾化吸入治疗),比对分析两组的临床疗效、体征消失时间与住院时间、治疗前后炎性反应与肺功能指标。结果研究组94.59%的治疗有效率高于对照组75.68%,差异有统计学意义(χ^(2)=5.232,P<0.05);研究组的退热、肺啰音、咳嗽消失时间与住院时间[(3.59±1.25)、(5.06±1.41)、(8.17±2.03)、(9.06±1.71)d]均短于对照组,治疗后,研究组患儿的EOS、IL-2、IL-4与FEV1、FEV1/FVC、PEF[(0.15±0.28)%、(186.60±27.21)ng/L、(5.46±0.96)ng/L、(2.97±0.63)L、(76.33±2.99)%、(93.91±5.19)L/min]均优于对照组,差异有统计学意义(t=2.193、3.794、6.062、7.552、2.300、7.627、4.550、5.784、13.647、15.216,P<0.05)。结论小儿支原体肺炎临床给予阿奇霉素序贯治疗联合特布他林雾化吸入治疗,可有效纠正患儿的炎性反应,在短时间内解除临床症状,优化肺功能,对患儿预后发展有促进意义。

Objective Observation of the effect of azithromycin combined with terbutaline nebulized inhalation in the treatment of mycoplasma pneumonia(MMP)in children.Methods The 74 children with MMP admitted to the hospital from April 2019 to April 2020 were included in the study and analysis.According to the order of admission time,they were divided into a control group(sequential azithromycin treatment)and a study group(sequential azithromycin+Terbutaline nebulized inhalation therapy),compared and analyzed the clinical efficacy of the two groups,the time of disappearance of signs and the length of hospitalization,inflammatory response and lung function indicators before and after treatment.Results The effective rate of 94.59%in the study group was higher than 75.68%in the control group,and the difference was statistically significant(χ^(2)=5.232,P<0.05);the disappearance time of fever,pulmonary rales,and cough in the study group was related to the length of hospital stay[(3.59±1.25)d,(5.06±1.41)d,(8.17±2.03)d,(9.06±1.71)d]were shorter than the control group,after treatment,the EOS,IL-2,IL-4 and FEV1,FEV1/FVC,PEF[(0.15±0.28)%,(186.60±27.21)ng/L,(5.46±0.96)ng/L,(2.97±0.63)L,(76.33±2.99)%,(93.91±5.19)L/min]were better than the control group,and the difference was statistically significant(t=2.193,3.794,6.062,7.552,2.300,7.627,4.550,5.784,13.647,15.216,P<0.05).Conclusion The clinical application of azithromycin sequential therapy combined with terbutaline nebulized inhalation therapy for mycoplasma pneumonia in children can effectively correct the inflammatory response in children.Relieving clinical symptoms in a short period of time and optimizing lung function are of great significance to the prognostic development of children.